Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Low Regimen Therapeutic Strategies to Mitigate TET2 Mutant Clonal Hematopoiesis

Dongxu Jiang, Daniel J Vail, Yahan Zhang, Raziullah Khan, Anand Tiwari, Simon Schlanger, Kunho Chung, Cassandra Gilmour, Xiaorong Gu, Yvonne Parker, J. Joseph Melenhorst, Daniel Lindner, Jaroslaw Maciejewski, Babal K. Jha

Blood (2024) 144 (Supplement 1): 2664.

https://doi.org/10.1182/blood-2024-211363

Published: 2024

Journal Articles

Age-Related Cellular Factors Facilitate TET2 Mutant Clonal Hematopoiesis

Daniel J Vail, Dongxu Jiang, Kunho Chung, Yahan Zhang, Sophia Martinez, Luca Guarnera, Yvonne Parker, J. Joseph Melenhorst, Daniel Lindner, Jaroslaw Maciejewski, Babal K. Jha

Blood (2024) 144 (Supplement 1): 1278.

https://doi.org/10.1182/blood-2024-211683

Published: 2024

Journal Articles

Developing a Therapeutic Strategy for Targeting Metabolic Vulnerability of TET2 Mutant Leukemia

Xiaorong Gu, Yahan Zhang, Songa Bae, Dongxu Jiang, Nakisha D Williams, Daniel Vail, Simon Schlanger, Jill Durkin, Yvonne Parker, Daniel Lindner, Jaroslaw Maciejewski, Babal K. Jha

Blood (2024) 144 (Supplement 1): 2918.

https://doi.org/10.1182/blood-2024-207470

Published: 2024

Journal Articles

A CD6-Targeted Antibody-Drug Conjugate As a Potential Therapy for T Cell-Mediated Disorders

Linjun Zhang, Liping Luo, Joel Chen, Rupesh Singh, William Baldwin, David A Fox, Daniel Lindner, Feng Lin

Blood (2021) 138 (Supplement 1): 3817.

https://doi.org/10.1182/blood-2021-145449

Published: 2021

Journal Articles

Therapeutic Targeting of TET-Dioxygenase Deficiency in Myeloid Malignancies

Yihong Guan, Anand D. Tiwari, Metis Hasipek, Dale Grabowski, Daniel Lindner, James G Phillips, Omar Mian, Mingjiang Xu, Jaroslaw P. Maciejewski, Babal K. Jha

Blood (2021) 138 (Supplement 1): 3985.

https://doi.org/10.1182/blood-2021-152744

Published: 2021

Journal Articles

Germline MPO Variants Predispose to Myeloid Neoplasia: Potential Mechanisms Suggested By In Vivo and in Vitro Studies

Blood (2021) 138 (Supplement 1): 3662.

https://doi.org/10.1182/blood-2021-149598

Published: 2021

Journal Articles

TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia

Yihong Guan, PhD, Anand D. Tiwari, PhD, James G Phillips, PhD, Metis Hasipek, PhD, Dale Grabowski, BS, Cassandra M Kerr, MS, Vera Adema, PhD, Yasunobu Nagata, MD PhD, Valeria Visconte, PhD, Tomas Radivoyevitch, PhD, Daniel Lindner, MD PhD, Manja Meggendorfer, PhD, Mohamed Abazeed, Mikkael A. Sekeres, MD MS, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 880.

https://doi.org/10.1182/blood-2019-131920

Published: 2019

Journal Articles

Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations

Xiaoxian Zhao, PhD, Bartlomiej Przychodzen, Juraj Bodo, PhD, Lisa Durkin, Daniel Lindner, MD PhD, Neetha Parameswaran, PhD, Michael Clemente, MS, Sarah L. Ondrejka, DO, Jaroslaw P. Maciejewski, MD PhD, Deepa Jagadeesh, MDMPH, Eric D. Hsi, MD

Blood (2019) 134 (Supplement_1): 1572.

https://doi.org/10.1182/blood-2019-129131

Published: 2019

Journal Articles

Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab

Neetha Parameswaran, PhD, Xiaoxian Zhao, PhD, Juraj Bodo, PhD, Lisa Durkin, Yvonne Parker, Daniel Lindner, MD PhD, Eric D. Hsi, MD, Deepa Jagadeesh, MDMPH

Blood (2019) 134 (Supplement_1): 1515.

https://doi.org/10.1182/blood-2019-131800

Published: 2019

Journal Articles

Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies

Blood (2018) 132 (Supplement 1): 211.

https://doi.org/10.1182/blood-2018-99-116411

Published: 2018

Journal Articles

Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases

Yihong Guan, Anand D. Tiwari, PhD, Metis Hasipek, PhD, Dale Grabowski, BS, Yvonne Parker, Cassandra M. Hirsch, Amy C Graham, BS, MS, Yasunobu Nagata, Bartlomiej P. Przychodzen, Aziz Nazha, Daniel Lindner, MD PhD, Tomas Radivoyevitch, PhD, James G Phillips, PhD, Jaroslaw P. Maciejewski, Babal K. Jha

Blood (2018) 132 (Supplement 1): 4345.

https://doi.org/10.1182/blood-2018-99-117186

Published: 2018

Journal Articles

Novel Therapeutic Targets for DNMT3A Mutant Myeloid Neoplasms

Vera Adema, PhD, Suresh K. Balasubramanian, MD, Cassandra M. Hirsch, BS, Bartlomiej P. Przychodzen, MSc, James G Phillips, PhD, Daniel Lindner, MD PhD, Tomas Radivoyevitch, PhD, Sudipto Mukherjee, MD PhD MPH, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Francesc Sole, PhD, Mikkael A. Sekeres, MD MS, Valeria Visconte, PhD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 106.

https://doi.org/10.1182/blood.V130.Suppl_1.106.106

Published: 2017

Journal Articles

Activation of Autophagy in Models of SF3B1 Mutant MDS

Blood (2017) 130 (Supplement 1): 4230.

https://doi.org/10.1182/blood.V130.Suppl_1.4230.4230

Published: 2017

Journal Articles

Targeting Autophagy in Myelodysplastic Syndromes

Valeria Visconte, PhD, Steffan T. Nawrocki, PhD, Bartlomiej P Przychodzen, MSc, Kevin R. Kelly, MD PhD, Mei Yin, Yvonne Parker, Michael J. Clemente, M.S., John Barnard, PhD, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Daniel Lindner, Heesun J Rogers, MD PhD, Jaroslaw P Maciejewski, MD PhD FACP, Jennifer S. Carew, PhD

Blood (2016) 128 (22): 4295.

https://doi.org/10.1182/blood.V128.22.4295.4295

Published: 2016

Journal Articles

Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes

Valeria Visconte, PhD, Bartlomiej P Przychodzen, MSc, Steffan T. Nawrocki, PhD, Swapna Thota, MD, Kevin R. Kelly, MD PhD, Bhumika Patel, MD, Cassandra M. Hirsch, BSc, Hetty E. Carraway, MD MBA, Yvonne Parker, Daniel Lindner, Mikkael A. Sekeres, MD MS, Heesun J Rogers, MD PhD, Jaroslaw P. Maciejewski, MD, PhD, FACP, Jennifer S. Carew, PhD

Blood (2016) 128 (22): 4301.

https://doi.org/10.1182/blood.V128.22.4301.4301

Published: 2016

Journal Articles

A Novel in Vitro Three Organ System Assay Identifies a Small Molecule Ubiquitin Analog with in Vivo Activity Against Myeloma

Sergei Vatolin, PhD, James G Phillips, PhD, Shravya Govindgari, Dale Grabowski, Yvonne Parker, Daniel Lindner, MD PhD, Claudiu Cotta, MD PhD, Frederic J. Reu, MD

Blood (2014) 124 (21): 2085.

https://doi.org/10.1182/blood.V124.21.2085.2085

Published: 2014

Journal Articles

Nitric Oxide As a Mediator of Bone Marrow Fibrosis in Patients with Myelofibrosis

Ali Tabarroki, MD, Daniel Lindner, MD PhD, Valeria Visconte, PhD, Nikolaos Papandantonakis, Jing Ai, MD PhD, Mikkael A. Sekeres, MD MS, Anjali S. Advani, MD, Matt E. Kalaycio, MD, Tracy Cinalli, RN, Kristin Colaluca, RN, Gina Rupp, John Desamito, Heesun J. Rogers, MD PhD, Ramon V. Tiu, MD

Blood (2014) 124 (21): 4587.

https://doi.org/10.1182/blood.V124.21.4587.4587

Published: 2014

Journal Articles

Triple Negative (J AK2 exon 12 /14 and MPL wild type) Myelofibrosis Have Higher Expression Of CDC25A and Greater Sensitivity To CDC25A Inhibition Compared To JAK2 Mutant Cases

Ali Tabarroki, MD, Valeria Visconte, PhD, Heesun J. Rogers, MD, PhD, Juraj Bodo, PhD, Li Zhang, Felicitas Lacbawan, Edy Hasrouni, John Barnard, Alan E. Lichtin, Daniel Lindner, Mikkael A. Sekeres, MD, MS, Ramon V. Tiu, MD

Blood (2013) 122 (21): 5259.

https://doi.org/10.1182/blood.V122.21.5259.5259

Published: 2013

Journal Articles

Modified Dose Escalation Of Ruxolitinib: A Feasible Therapeutic Approach In The Management Of Myelofibrosis

Ali Tabarroki, MD, Daniel Lindner, Valeria Visconte, PhD, Heesun J. Rogers, MD, PhD, John Desamito, Hien K. Duong, MD, Alan E. Lichtin, Anjali S. Advani, MD, Ronald M. Sobecks, MD, Tracy Cinalli, RN, Kristin Dodd, RN, Jing Ai, MD, PhD, Yogen Saunthararajah, M.D., Matt Kalaycio, MD, Brady L. Stein, MD, Mikkael A. Sekeres, MD, MS, Ramon V. Tiu, MD

Blood (2013) 122 (21): 1586.

https://doi.org/10.1182/blood.V122.21.1586.1586

Published: 2013

Journal Articles

Splicing Factor 3b Subunit 1 ( SF3B1) mediates Mitochondrial Iron Overload In Myelodysplastic Syndromes With Ring Sideroblasts By Alternative Splicing Of Mitoferrin-1 ( SLC25A37 )

Blood (2013) 122 (21): 1555.

https://doi.org/10.1182/blood.V122.21.1555.1555

Published: 2013

NARROW

Low Regimen Therapeutic Strategies to Mitigate TET2 Mutant Clonal Hematopoiesis

Age-Related Cellular Factors Facilitate TET2 Mutant Clonal Hematopoiesis

Developing a Therapeutic Strategy for Targeting Metabolic Vulnerability of TET2 Mutant Leukemia

A CD6-Targeted Antibody-Drug Conjugate As a Potential Therapy for T Cell-Mediated Disorders

Therapeutic Targeting of TET-Dioxygenase Deficiency in Myeloid Malignancies

Germline MPO Variants Predispose to Myeloid Neoplasia: Potential Mechanisms Suggested By In Vivo and in Vitro Studies

TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia

Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations

Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab

Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies

Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases

Novel Therapeutic Targets for DNMT3A Mutant Myeloid Neoplasms

Activation of Autophagy in Models of SF3B1 Mutant MDS

Targeting Autophagy in Myelodysplastic Syndromes

Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes

A Novel in Vitro Three Organ System Assay Identifies a Small Molecule Ubiquitin Analog with in Vivo Activity Against Myeloma

Nitric Oxide As a Mediator of Bone Marrow Fibrosis in Patients with Myelofibrosis

Triple Negative (J AK2 exon 12 /14 and MPL wild type) Myelofibrosis Have Higher Expression Of CDC25A and Greater Sensitivity To CDC25A Inhibition Compared To JAK2 Mutant Cases

Modified Dose Escalation Of Ruxolitinib: A Feasible Therapeutic Approach In The Management Of Myelofibrosis

Splicing Factor 3b Subunit 1 ( SF3B1) mediates Mitochondrial Iron Overload In Myelodysplastic Syndromes With Ring Sideroblasts By Alternative Splicing Of Mitoferrin-1 ( SLC25A37 )

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only